FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine non-small cell lung cancer

By afschroeder • June 26, 2026

Abascal J, Dumitras C, Tran LM, Crosson W, Kahangi B, Oh M, Rennels A, Lim RJ, Jiang H, Reyimjan D, Coleman NJ, Perez-Reyes E, Chin S, Krysan K, Dubinett SM, Liu B, Salehi-Rad R. FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine non-small cell lung cancer. J Immunother Cancer. 2026 Jun 25;14(6):e014914. doi: 10.1136/jitc-2026-014914. PMID: 42350046.

Tags: Dendritic, Hematology/Oncology, immunotherapy, Lung cancer, Publications, Pulmonary, Critical Care & Sleep Medicine, vaccine, Veterans Administration

Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]

Wu YL, Majem M, John T, Grohé C, Wang J, Goldman JW, Lu S, Shepherd FA, Wang Q, Kato T, Aokage K, Zhong WZ, Laktionov[...]

Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma

Paniker AG, Marshalek JP, Chao E, Yashar D, Tomassetti S. Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma. J Hematol. 2026 Aug 31;15(4):188-197.[...]

Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank

Msaouel P, La Rosa S, Abel EJ, Albiges L, Barata PC, Berg SA, Braun DA, Brugarolas J, Campbell MT, Carlo MI, Coleman K, Cost NG,[...]